儿科患者直接使用口服抗凝剂的模式:来自多中心国家数据库的结果
Molly Mack1, Frederico Xavier1, Meghan McCormick2
1Department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USA.
Pediatric blood & cancer
|May 26, 2025
概括
直接口服抗凝剂 (DOAC) 越来越多地用于儿科静脉血栓事件 (VTE). 处方模式受患者年龄,收入和并发症的影响,而不仅仅是临床证据.
科学领域:
- 儿科血液学 儿科血液学
- 药理学 药理学是指药理学的学科.
- 临床儿科 临床儿科
背景情况:
- 直接口服抗凝剂 (DOAC) 提供了诸如口服和减少监测等优势.
- 它们在儿科静脉血栓事件 (VTE) 中的使用正在增长.
- 本研究研究了影响VTE儿童DOAC选择的趋势和因素.
研究的目的:
- 评估诊断出新的静脉血栓事件 (VTE) 的儿科患者中直接口服抗凝剂 (DOAC) 的使用趋势.
- 在这个患者群体中确定与DOAC选择相关的因素.
主要方法:
- 对儿科健康信息系统 (PHIS) 数据库的回顾性分析.
- 从2014年到2021年,包括儿童 (0-18岁) 患有VTE的住院治疗.
- 患者特征和后勤回归的比较,以确定与DOAC使用相关的因素.
主要成果:
- 在20332例儿科VTE病例中,DOAC被用于3.98%的病例,到2021年,使用率将上升到12.0%.
- 接受DOAC的受益者年龄较大,收入更高,更有可能拥有私人保险.
- 使用DOAC与更短的住院时间,更低的成本和更少的复杂慢性疾病有关.
结论:
- 在患有静脉血栓事件 (VTE) 的儿科患者中,直接口服抗凝剂 (DOAC) 的使用正在增加.
- 患者年龄,社会经济地位和并发症等因素会影响DOAC的处方.
- 处方趋势可能不仅仅依赖于临床证据,突出需要进一步调查.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
934
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
934
Venous Thrombosis III: Interprofessional Care
29
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
29
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
64
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
64


